Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment reporting

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
SYF11dd4a5751c54300a4096f9797d78c98Phase 3Recruiting

Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and placebo on patients with recurrent herpes labialis

Role: lead

SYF890968076700479297e7195ba7ce8193Phase 2Active Not Recruiting

An exploratory, multicenter, randomized, open-label with blind evaluation, active controlled study to evaluate the safety and efficacy of Keramod (imiquimod 50 mg/g, Gel) compared with Aldara (imiquimod 50 mg/g, Cream) for the treatment of actinic keratosis in adults.

Role: lead

SYFbdded54e21a9432bb98b1696a055a474Phase 3Recruiting

Clinical trial to evaluate the efficacy and safety of the topical application of Impetine® Gel (mupirocin 20 mg/g) compared with Bactroban® Ointment (mupirocin 20 mg/g) for the treatment of impetigo in paediatric population.

Role: lead

All 3 trials loaded